Skip to main content
Premium Trial:

Request an Annual Quote

ACT Genomics Raises $8M in Private Funding Round

NEW YORK (GenomeWeb) – ACT Genomics today announced it has raised more than $8 million in its first private funding round.

The funds will support further investment in the firm's lineup of molecular diagnostic assays for monitoring cancer and expansions in the firm's sales, marketing, and medical teams.

"The additional capital will allow us to continue building robust molecular assays and [an] innovative bioinformatics engine," ACT Genomics CEO Hua-Chien Chen said in a statement.

Taipei, Taiwan-based ACT Genomics has developed two molecular diagnostic assays for oncology, ACTDrug and ACTOnco. The firm characterizes itself as a molecular information service company and uses a multiplex molecular test platform along with next-generation sequencing and proprietary bioinformatics in developing its assays.

The company also serves as an Ion Torrent certified service provider.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.